Hepatitis treatment coverage among diagnosed population
Topic:
Hepatitis
Hepatitis treatment and care
Health service coverage
Rationale:
Measures progress towards providing treatment to all people with chronic hepatitis C and treatment coverage for people with hepatitis B among those eligible. This indicator is essential to measurement of the programmatic targets for the path to elimination and full validation of elimination of hepatitis C as a public health threat by 2030.
Definition:
• Percentage of people diagnosed with chronic hepatitis B initiating treatment among those eligible
• Percentage of people diagnosed with chronic hepatitis C infection who have been initiated on treatment
Disaggregation:
By country and WHO region
Method of measurement
Country-reported data: The indicator is compiled from routine national programme, surveillance, laboratory, clinical or health information system records. Data should cover the reporting year and the geographical and population scope reported by the country. Countries should describe whether the data are national or subnational, which sectors and facilities are included, and whether individual-level deduplication or record linkage is used.
HBV:
Numerator: Number of people with chronic hepatitis B ever initiated on treatment of those eligible.
Denominator: Number of people ever diagnosed with chronic HBV.
HCV:
Numerator :Number of people with viraemic hepatitis C ever initiated on treatment.
Denominator: Number of people ever diagnosed with viraemic HCV since 2015.
For chronic HCV the denominator includes those with resolved infection (cured or naturally cleared) . all total HCV infections (all ages) since 2015. This intended to reflect the historical testing effort and treatment coverage. Those with re-infection are included but counted once.
Modelled estimates: Where complete country-reported data are unavailable, WHO may produce a country-calibrated estimate using available programme data, epidemiological evidence, demographic data and other relevant inputs. The modelled estimate is intended to provide a coherent value for the specified reference year and may not equal a value reported directly by the country.
Method of estimation:
HBV model structure (PRoGReSs model): the HBV model uses a dynamic mathematical framework that estimates annual HBV prevalence and incidence by stage of liver disease, age and sex using disease progression and mortality (all-cause and liver-related) rates. The model integrates demographic profiles, vaccination coverage (including timely birth dose and three-dose infant
series), prevention measures such as hepatitis B immune globulin (HBIG) and maternal antiviral prophylaxis, HBV diagnosis and treatment schedules, and established HBV epidemiological parameters. Perinatal, early childhood and horizontal transmission are modelled using age-specific hepatitis B surface antigen (HBsAg) prevalence together with available prevention-coverage data. This allows the model to reflect both historical and current programme performance.
HCV model structure: the HCV model employs a Markov/semi-dynamic natural history framework that follows people with viraemic infection across stages of liver disease, by age and sex, over time using disease progression and mortality (all-cause and liver-related) rates. It incorporates inputs from demographic profiles, HCV diagnosis and treatment initiation schedules, and subsequent cure (sustained virological response, SVR).
Method of estimation of global and regional aggregates:
Estimates are also produced at global level and for WHO regions
Preferred data sources:
Surveillance systems
Facility registers and other program monitoring tools
Facility reporting system
Unit of Measure:
Percent
Expected frequency of data dissemination:
Every two years
Expected frequency of data collection:
Continuous
Comments:
Comparability and Interpretation: This indicator reflects progression through the care cascade and should be interpreted in conjunction with diagnosis coverage. Differences between countries may reflect reporting and monitoring system maturity rather than programme performance alone.
This dataset contains a combination of country-reported data and WHO-supported modelled estimates. Values may differ because they are derived from different data sources, population coverage, reference years and methodologies. Country-reported data are intended primarily for national programme monitoring, whereas modelled estimates are intended to support standardized comparisons across countries and over time. Direct comparisons between country-reported and modelled values, or between countries represented by different observation types, should therefore be made with caution. Differences between WHO estimates and official national figures should not necessarily be interpreted as errors but may reflect methodological and data-source differences.
Coverage estimates may be influenced by incomplete reporting of diagnosed persons, treatment initiation records and patient outcomes. Variations in data linkage capacity and patient tracking systems may affect accuracy.
If you have any feedback, you are welcome to write it here.
If you need to access the old Global Health Observatory data, you can do it here. But before you leave, please provide us your feedback about our new data portal.